Mabthera® (Rituximab) for the Treatment of Severe Granulomatosis With Polyangiitis (Gpa) and Microscopic Polyangiitis (Mpa) – A Cost-Utility Model for the United Kingdom
Abstract
Authors
D. Harland B. Naisbett-Groet S. Chang D.K. Sungher L. Sawyer A. Diamantopoulos